Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

AT Shaw, L Gandhi, S Gadgeel, GJ Riely… - The lancet …, 2016 - thelancet.com
Background Alectinib—a highly selective, CNS-active, ALK inhibitor—showed promising
clinical activity in crizotinib-naive and crizotinib-resistant patients with ALK-rearranged (ALK …
被引用次数：706 相关文章
[PDF] escholarship.org

[PDF][PDF] Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

AT Shaw, L Gandhi, S Gadgeel, GJ Riely… - The Lancet …, 2016 - escholarship.org
Background—Alectinib, a highly selective, central nervous system (CNS)-active anaplastic
lymphoma kinase (ALK) inhibitor, demonstrated promising clinical activity in crizotinib-naïve …
[PDF] academia.edu

[PDF][PDF] Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group

AT Shaw, L Gandhi, S Gadgeel - The Lancet Oncology, 2016 - academia.edu
Background—Alectinib, a highly selective, central nervous system (CNS)-active anaplastic
lymphoma kinase (ALK) inhibitor, demonstrated promising clinical activity in crizotinib-naïve …

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

AT Shaw, L Gandhi, S Gadgeel… - The Lancet …, 2016 - pubmed.ncbi.nlm.nih.gov
Background Alectinib--a highly selective, CNS-active, ALK inhibitor-showed promising
clinical activity in crizotinib-naive and crizotinib-resistant patients with ALK-rearranged (ALK …

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: A single-group, multicentre, phase 2 trial

AT Shaw, L Gandhi, S Gadgeel… - The lancet …, 2016 - mdanderson.elsevierpure.com
Background: Alectinib-a highly selective, CNS-active, ALK inhibitor-showed promising
clinical activity in crizotinib-naive and crizotinib-resistant patients with ALK-rearranged (ALK …

[引用][C] Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

AT Shaw, L Gandhi, S Gadgeel, GJ Riely, J Cetnar… - The Lancet …, 2016 - cir.nii.ac.jp
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group,
multicentre, phase 2 trial | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

AT Shaw, L Gandhi, S Gadgeel, GJ Riely, J Cetnar… - The Lancet …, 2016 - Elsevier
Background Alectinib—a highly selective, CNS-active, ALK inhibitor—showed promising
clinical activity in crizotinib-naive and crizotinib-resistant patients with ALK-rearranged (ALK …

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: A single-group, multicentre, phase 2 trial

AT Shaw, L Gandhi, S Gadgeel… - The Lancet …, 2016 - ohiostate.elsevierpure.com
Background: Alectinib-a highly selective, CNS-active, ALK inhibitor-showed promising
clinical activity in crizotinib-naive and crizotinib-resistant patients with ALK-rearranged (ALK …

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

AT Shaw, L Gandhi, S Gadgeel, GJ Riely… - The Lancet …, 2015 - europepmc.org
Background Alectinib--a highly selective, CNS-active, ALK inhibitor-showed promising
clinical activity in crizotinib-naive and crizotinib-resistant patients with ALK-rearranged (ALK …

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: A single-group, multicentre, phase 2 trial

AT Shaw, L Gandhi, S Gadgeel, GJ Riely… - The Lancet …, 2016 - ohsu.elsevierpure.com
Background: Alectinib-a highly selective, CNS-active, ALK inhibitor-showed promising
clinical activity in crizotinib-naive and crizotinib-resistant patients with ALK-rearranged (ALK …